724743-88-8

Basic information

• Product Name: 5-[(3,4-dioxo-3,4-dihydro-1-naphthalenyl)amino]-2-naphthalenesulfonic acid
• Synonyms: 5-[(3,4-dioxo-3,4-dihydro-1-naphthalenyl)amino]-2-naphthalenesulfonic acid
• CAS NO: 724743-88-8
• Molecular Formula: C20H13NO5S
• Molecular Weight: 379.38592
• Mol File: 724743-88-8.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5-[(3,4-dioxo-3,4-dihydro-1-naphthalenyl)amino]-2-naphthalenesulfonic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 5-[(3,4-dioxo-3,4-dihydro-1-naphthalenyl)amino]-2-naphthalenesulfonic acid(724743-88-8)
• EPA Substance Registry System: 5-[(3,4-dioxo-3,4-dihydro-1-naphthalenyl)amino]-2-naphthalenesulfonic acid(724743-88-8)

Safety Data

• Hazardous Substances Data: 724743-88-8(Hazardous Substances Data)

Upstream product

• 119-79-9 5-aminonaphthalene-2-sulfonic acid 
• 521-24-4 sodium 1,2-naphthoquinone-4-sulfonate 

Relevant articles and documents

Discovery of Small-Molecule Inhibitors of the HSP90-Calcineurin-NFAT Pathway against Glioblastoma

Glioblastoma (GBM) is among the most common and malignant types of primary brain tumors in adults, with a dismal prognosis. Although alkylating agents such as temozolomide are widely applied as the first-line treatment for GBM, they often cause chemoresis

1,2- two alkone naphthalene compound and its preparation method and application

The invention discloses a 1,2-diketone naphthalene compound which has a general structural formula (I) described in the specification, wherein Ar represents benzene ring, naphthalene ring, quinoline ring or isoquinoline ring, naphthalene diimide ring or coumarin ring; amino acid is directly connected with the Ar; when a substituent group exists on the Ar, R is an electron-withdrawing, electron-donating or neutral group. The invention further discloses a preparation method of the compound and application of the compound to preparation of inflammation-resistant and immunocompetence-resistant drugs. The compound is relatively good in inflammation and immunological competence resistance, is a CRAC (Ca release activated Ca) blocker with a novel structure, and can be used as a lead compound of the inflammation-resistant and immunocompetence-resistant drugs. According to the preparation method, the reaction condition is mild, raw materials are cheap and easily available, and the operation and the post-treatment process are simple.